Gallium maltolate

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H529419

CAS#: 108560-70-9

Description: Gallium maltolate is a ribonucleoside-diphosphate reductase inhibitor potentially for the treatment of prostate cancer

Chemical Structure

img
Gallium maltolate
CAS# 108560-70-9
Instruction

Theoretical Analysis

Hodoodo Cat#: H529419
Name: Gallium maltolate
CAS#: 108560-70-9
Chemical Formula: C18H15GaO9
Exact Mass: 444.00
Molecular Weight: 445.030
Elemental Analysis: C, 48.58; H, 3.40; Ga, 15.67; O, 32.36

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Gallium maltolate

IUPAC/Chemical Name: gallium tris(2-methyl-4-oxo-4H-pyran-3-olate)

InChi Key: ASYYOZSDALANRF-UHFFFAOYSA-K

InChi Code: InChI=1S/3C6H6O3.Ga/c3*1-4-6(8)5(7)2-3-9-4;/h3*2-3,8H,1H3;/q;;;+3/p-3

SMILES Code: [O-]C1=C(C)OC=CC1=O.[O-]C2=C(C)OC=CC2=O.[O-]C3=C(C)OC=CC3=O.[Ga+3]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 445.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Picken C, Fragkos KC, Eddama M, Coghlan G, Clapp LH. Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. J Clin Med. 2019 Apr 9;8(4). pii: E481. doi: 10.3390/jcm8040481. PubMed PMID: 30970653.
2: Verlinden NJ, Walter C, Kanwar M, Raina A. Transition From Oral Treprostinil to Selexipag in a Patient With Pulmonary Arterial Hypertension. Ann Pharmacother. 2019 Apr 4:1060028019843665. doi: 10.1177/1060028019843665. [Epub ahead of print] PubMed PMID: 30947510.
3: You R, Qian X, Tang W, Xie T, Zeng F, Chen J, Zhang Y, Liu J. Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review. Can Respir J. 2018 Nov 18;2018:1015239. doi: 10.1155/2018/1015239. eCollection 2018. Review. PubMed PMID: 30581511; PubMed Central PMCID: PMC6276424.
4: Hopper RK, Rogers R, Lawrence KM, Hedrick HL. Reply. J Pediatr. 2019 Mar;206:305-306. doi: 10.1016/j.jpeds.2018.11.033. Epub 2018 Dec 14. PubMed PMID: 30559025.
5: Madenci AL, Baer HJ, Vitali SH, Zalieckas JM, Arnold JH, Weldon CB. Time versus treatment: interpreting longitudinal data analysis of treprostinil. J Pediatr. 2019 Mar;206:304-305. doi: 10.1016/j.jpeds.2018.11.034. Epub 2018 Dec 14. PubMed PMID: 30559020.
6: Themanns M, Koban F, Bergmayr C, Chrzan A, Strohmaier W, Haybaeck J, Freissmuth M, Zebedin-Brandl E. Treprostinil reduces endothelial damage in murine sinusoidal obstruction syndrome. J Mol Med (Berl). 2019 Feb;97(2):201-213. doi: 10.1007/s00109-018-1726-6. Epub 2018 Dec 7. PubMed PMID: 30535954; PubMed Central PMCID: PMC6348071.
7: Bacha NC, Levy M, Guerin CL, Le Bonniec B, Harroche A, Szezepanski I, Renard JM, Gaussem P, Israel-Biet D, Boulanger CM, Smadja DM. Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension. Pediatr Pulmonol. 2019 Jan;54(1):66-72. doi: 10.1002/ppul.24190. Epub 2018 Nov 28. PubMed PMID: 30485728.
8: Ghofrani HA. Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension? Lancet Respir Med. 2019 Mar;7(3):191-193.
doi: 10.1016/S2213-2600(18)30369-2. Epub 2018 Nov 23. PubMed PMID: 30477764.
9: Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. 2019 Mar;7(3):239-248. doi: 10.1016/S2213-2600(18)30367-9. Epub 2018 Nov 23. PubMed PMID: 30477763.
10: Wang S, Yu M, Zheng X, Dong S. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. Drug Deliv. 2018 Nov;25(1):1898-1909. doi: 10.1080/10717544.2018.1523257. PubMed PMID: 30442035; PubMed Central PMCID: PMC6249551.
11: Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE,
Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. J Heart Lung Transplant. 2019 Jan;38(1):43-50. doi: 10.1016/j.healun.2018.09.003. Epub 2018 Sep 12. PubMed PMID: 30391194.
12: Lambers C, Kornauth C, Oberndorfer F, Boehm PM, Tamm M, Klepetko W, Roth M. Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial
smooth muscle cells. PLoS One. 2018 Nov 1;13(11):e0205195. doi: 10.1371/journal.pone.0205195. eCollection 2018. PubMed PMID: 30383775; PubMed Central PMCID: PMC6211661.
13: Ochman M, Urlik M, Tatoj Z, Wajda-Pokrontka M, Zawadzki F, Latos M, Zembala M. Lung transplantation as a viable option of treatment for pulmonary veno-occlusive disease. Adv Respir Med. 2018;86(5):249-254. doi: 10.5603/ARM.2018.0040. PubMed PMID: 30378654.
14: Wang T, Lu J, Li Q, Chen Y, Ye Q, Gao J, Yang D, Zhao L, Huang J, Zhang J. Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study. Anesth
Analg. 2018 Oct 12. doi: 10.1213/ANE.0000000000003827. [Epub ahead of print] PubMed PMID: 30320651.
15: Alsheikh B, Aljohani O, Coufal NG. Paediatric pulmonary hypertension caused by an ACVRL1 mutation presenting as Ortner syndrome. Cardiol Young. 2018 Dec;28(12):1475-1476. doi: 10.1017/S1047951118001531. Epub 2018 Oct 10. PubMed PMID: 30303062; PubMed Central PMCID: PMC6237639.
16: Fanous SM, Janmohamed M. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series. Am J Health Syst Pharm. 2018 Dec 1;75(23):1877-1881. doi: 10.2146/ajhp170814. Epub 2018 Oct 9. PubMed PMID: 30301721.
17: Richter MJ, Harutyunova S, Bollmann T, Classen S, Gall H, Gerhardt Md F, Grimminger F, Grimminger J, Grünig E, Guth S, Halank M, Heine A, Hoeper MM, Klose H, Lange TJ, Meyer K, Neurohr C, Nickolaus K, Olsson KM, Opitz CF, Rosenkranz S,
Seyfarth HJ, Warnke C, Wiedenroth C, Ghofrani HA, Ewert R. Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. J Heart Lung Transplant. 2018 Oct;37(10):1235-1244. doi: 10.1016/j.healun.2018.06.006. Epub 2018 Jun 21. PubMed PMID: 30293617.
18: Lombardi S, Kingman M, Duncan M, Berngard SC, Fernandes T. Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations. Respir Med. 2018 Oct;143:139-146. doi: 10.1016/j.rmed.2018.09.002. Epub 2018 Sep 5. Review. PubMed PMID: 30261985.
19: Enderby CY, Burger C. Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension. Ther Adv Chronic Dis. 2018 Jun 3;9(9):171-177. doi: 10.1177/2040622318779749. eCollection. 2018 Sep. PubMed PMID: 30181846; PubMed Central PMCID: PMC6116084.
20: Maestas T, Hansen LM, Vanderpool RR, Desai AA, Airhart S, Knapp SM, Cohen A,
Feldman J, Rischard FP. Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension. Pulm Circ. 2018 Oct-Dec;8(4):2045894018797270. doi: 10.1177/2045894018797270. Epub 2018 Aug 20. PubMed PMID: 30124133; PubMed Central PMCID: PMC6122247.